This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of peginterferon beta-1a
MSMED_PEGINTERFERONBETA1A
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
152 |
4. Check minimum number of events
Min. number of events
3
|
152 |
5. Include endpointsNone |
152 |
6. Filter based on genotype QC (FinnGen only) |
138 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of peginterferon beta-1a
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- Other degenerative diseases of the nervous system
- Autoimmune diseases related-to ILD
- Autoimmune diseases
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 138 | 116 | 22 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.01 |
| Median age at first event (years) | 40.48 | 38.63 | 50.21 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 150
- Matched controls
- 1500
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L03AB13
ATC
peginterferon beta-1a; parenteral
+∞
216.8
150
*
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
201.5
150
10
109
Kela drug reimbursment
Multiple sclerosis
+∞
201.5
150
10
G35
ICD-10 Finland
Multiple sclerosis
+∞
198.1
150
13
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
2674.5
181.1
141
8
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
35.8
115.4
104
89
TAB00
NOMESCO Finland
Lumbar puncture
31.5
94.9
74
45
L03AB07
ATC
interferon beta-1a; parenteral
276.7
67.2
64
*
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
112.6
58.6
61
9
H46
ICD-10 Finland
Optic neuritis
131.0
50.7
52
6
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
12.2
49.8
66
91
L04AA31
ATC
[U] teriflunomide
+∞
45.1
41
*
N86
ICPC
Multiple sclerosis
168.1
37.7
38
*
L03AX13
ATC
glatiramer acetate; parenteral
97.2
34.7
37
5
XA800
NOMESCO Finland
Neuropsychological investigation
13.6
34.5
36
34
L04AX07
ATC
dimethyl fumarate; oral
93.7
33.6
36
5
N04BB01
ATC
amantadine; oral
357.4
29.9
29
*
N07XX09
ATC
[U] dimethyl fumarate
124.0
28.8
30
*
XCK00
NOMESCO Finland
Perimetry
12.2
26.5
29
29
L03AB08
ATC
interferon beta-1b; parenteral
269.5
23.3
23
*
164
Kela drug reimbursment
Fingolimod
127.9
21.2
22
*
G04BD12
ATC
mirabegron; oral
8.1
20.5
31
47
L04AG12
ATC
ofatumumab; parenteral
+∞
20.3
19
*
R20.2
ICD-10 Finland
Paraesthesia of skin
6.3
20.1
41
85
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
8.5
18.4
26
36
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
7.0
17.4
30
52
353
Kela drug reimbursment
Cladribine and fingolimod
101.6
17.0
18
*
2AB04, ,
NOMESCO Finland
190.3
16.9
17
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.8
16.1
46
127
L04AK02
ATC
teriflunomide; oral
+∞
15.9
15
*
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
23.2
15.6
22
11
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
13.5
15.5
27
24
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
21.9
14.7
21
11
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.8
14.5
30
62
XKD00
NOMESCO Finland
Uroflowmetry
7.6
14.5
22
33
XKD06
NOMESCO Finland
Physiologic investigation of micturition
22.8
14.2
20
10
XCW99
NOMESCO Finland
Other investigative procedure of eye
6.1
14.0
27
52
ZX120
NOMESCO Finland
Intravenous
6.2
13.8
26
49
L04AA27
ATC
[U] fingolimod
+∞
13.7
13
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
17.5
13.0
20
13
C10AC01
ATC
colestyramine; oral
17.5
13.0
20
13
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
6.0
13.0
25
48
L04AX09
ATC
diroximel fumarate; oral
141.3
12.6
13
*
H02AB04
ATC
methylprednisolone; systemic
4.5
12.4
36
99
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
70.6
11.8
13
*
XKC03
NOMESCO Finland
Water cystometry
16.1
10.3
16
11
XKD03
NOMESCO Finland
Urethral pressure profilometry
23.5
9.5
13
6
R42
ICD-10 Finland
Dizziness and giddiness
3.4
9.1
40
145
G04BD09
ATC
trospium; oral
25.9
9.1
12
5
TKC22
NOMESCO Finland
Catheterisation instruction
53.2
8.8
10
*
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
8.2
8.8
19
26
XCD10
NOMESCO Finland
Electrophysiological examination of eye
11.0
8.2
15
15
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
4.7
8.0
20
48
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
47.5
7.8
9
*
M03BX01
ATC
baclofen; systemic
12.8
7.7
13
11
UKC02
NOMESCO Finland
Cystoscopy
4.1
7.5
22
60
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
11.7
7.5
13
12
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
7.3
7
*
N39.4
ICD-10 Finland
Other specified urinary incontinence
6.1
7.2
19
35
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
14.7
7.0
11
8
ZY010
NOMESCO Finland
Hospital outpatient
4.2
6.8
19
50
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
9.4
6.7
13
15
Z2445
NOMESCO Finland
Psychologist
4.3
6.7
18
46
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
8.0
6.6
14
19
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
15.2
6.5
10
7
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
6.3
6
*
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
9.2
6.2
12
14
R4110
NOMESCO Finland
Physiotherapy
2.6
6.1
45
214
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
46
14
46.95
74.24
1.0
1.0
—
—
—
0
0
50
33
22.23
59.99
1.3
1.1
—
—
—
0
0
39
19
27.39
53.13
1.1
1.1
—
—
—
0
0
39
19
27.39
53.13
1.1
1.2
—
—
—
0
0
38
20
25.11
50.04
1.1
1.2
—
—
—
0
0
48
47
14.55
45.58
1.6
1.4
0.01
0.01
iu/ml
—
6
8
40
38
13.99
38.35
1.1
1.1
13.33
20.36
e6/l
0.15
30
28
40
38
13.99
38.35
1.1
1.2
84.07
34.59
e6/l
0.32
30
29
39
12
43.28
31.94
1.2
1.1
1.12
0.52
ratio
—
19
7
34
14
30.94
25.78
1.0
1.1
0.97
0.99
u/l
—
10
7
27
5
65.24
23.97
1.7
1.2
—
—
—
0
0
136
770
9.21
19.22
12.5
8.7
3.03
3.94
e9/l
7.78
125
676
17
10
18.96
11.50
1.6
2.0
9.53
11.50
%
—
17
10
86
449
3.15
10.81
2.7
4.6
38.89
37.94
g/l
1.24
76
431
130
872
4.68
10.79
6.5
4.3
—
1669.00
—
0
8
18
16
12.60
10.38
1.1
1.0
—
—
—
0
0
16
11
16.10
10.26
1.1
1.1
1717.31
1477.18
miu/ml
0.27
16
11
14
9
16.99
9.23
1.1
2.1
—
—
—
0
0
72
368
2.84
8.97
3.7
2.8
—
—
—
0
0
26
73
4.10
8.57
1.4
1.4
—
—
—
0
0
14
13
11.74
7.98
3.0
2.2
0.81
0.94
e9/l
0.38
14
13
59
299
2.60
7.16
3.8
2.4
0.14
0.19
e6/l
0.18
50
199
105
722
2.51
6.29
4.5
3.3
0.00
0.00
estimate
-0.00
24
148
104
730
2.38
5.67
4.5
3.4
0.00
0.00
estimate
-0.00
23
148
102
716
2.33
5.47
4.5
3.3
0.00
0.00
estimate
-0.00
24
155
128
1015
2.78
4.92
4.6
3.1
31.06
32.88
u/l
0.21
123
986
37
176
2.46
4.92
3.6
2.3
0.83
0.93
e6/l
0.09
20
76
150
1383
+∞
4.81
21.4
9.3
25.55
24.95
u/l
0.23
150
1356
144
1276
4.21
4.23
6.7
5.6
1.63
1.68
mu/l
0.30
144
1225
30
144
2.35
3.87
1.3
2.5
3.46
5.31
umol/l
2.75
25
119
34
182
2.12
3.36
2.5
2.3
7828.30
3891.49
u/l
0.37
11
79
32
170
2.12
3.22
3.9
2.3
2.00
4.67
e6/l
1.29
15
70
5
5
10.28
3.00
1.0
6.0
319.80
313.20
u/ml
—
5
5
65
461
1.72
2.66
1.6
1.9
89.14
94.94
pmol/l
0.65
38
255
86
679
1.62
2.21
2.9
5.0
5.73
6.23
mmol/l
3.15
77
600
144
1338
2.90
2.18
10.8
11.2
15.22
19.92
mg/l
1.26
107
1053
8
25
3.32
2.13
1.9
1.1
9.45
10.38
g/l
—
8
25
8
27
3.07
1.96
1.9
1.3
2.30
2.80
g/l
—
8
27
43
295
1.64
1.90
1.6
1.4
18.28
20.74
nmol/l
0.79
38
268
8
29
2.85
1.82
1.9
1.3
2.76
3.72
g/l
—
8
29
8
29
2.85
1.82
1.9
1.3
4.10
4.72
g/l
—
8
29
8
29
2.85
1.82
1.9
1.3
6.30
7.08
g/l
—
8
29
57
430
1.53
1.66
3.6
2.7
0.00
0.02
estimate
0.80
22
126
50
368
1.54
1.63
4.4
3.4
0.00
0.00
estimate
-0.00
23
150
5
14
3.66
1.63
1.0
1.4
—
—
—
0
0
132
1201
1.83
1.60
23.3
13.8
13.29
13.29
%
0.01
132
1192
7
26
2.77
1.60
2.1
1.3
1.73
1.27
g/l
—
7
26
109
1209
0.64
1.56
3.0
3.3
1.13
1.18
mmol/l
0.47
103
1147
11
51
2.25
1.54
1.8
1.6
66.42
3.38
u/ml
—
5
11
62
485
1.47
1.49
3.3
7.7
1.23
1.21
mmol/l
0.78
54
428
5
122
0.39
1.45
1.2
1.8
—
—
—
0
0
27
176
1.65
1.44
1.3
1.6
59.82
58.06
ug/l
0.08
22
152
119
1290
0.62
1.43
3.4
3.8
1.44
1.50
mmol/l
0.87
113
1239
41
540
0.67
1.37
1.5
1.8
1.17
1.32
mmol/l
1.09
36
488
67
539
1.44
1.37
4.1
3.1
0.00
0.01
estimate
0.50
22
134
55
428
1.45
1.34
2.5
6.9
1.23
1.21
mmol/l
0.67
49
408
6
24
2.56
1.31
1.0
1.0
0.00
0.00
g/l
—
6
24
11
55
2.08
1.31
1.3
1.3
—
—
—
0
0
120
1292
0.64
1.26
3.3
3.9
4.75
4.73
mmol/l
0.12
113
1243
6
25
2.46
1.25
1.0
1.0
0.00
0.00
g/l
—
6
25
5
20
2.55
1.16
1.4
1.3
—
—
—
0
0
45
347
1.42
1.13
1.8
2.0
2.40
2.65
mg/l
0.40
39
306
121
1295
0.66
1.12
3.3
4.1
2.88
2.81
mmol/l
0.40
114
1244
7
32
2.24
1.09
2.0
3.9
26.74
23.90
mmol/l
—
7
32
132
1232
1.60
1.05
9.4
9.0
99.35
95.82
ml/min/173m2
1.48
115
1115
42
326
1.40
1.01
1.8
2.0
—
—
—
0
0
150
1471
+∞
0.99
29.6
18.0
40.10
40.35
%
0.30
150
1462
150
1470
+∞
0.98
29.5
17.6
89.77
90.02
fl
0.33
150
1462
7
36
1.99
0.98
1.3
1.5
—
—
—
0
0
5
102
0.47
0.93
4.4
5.3
—
—
—
0
0
23
163
1.49
0.89
1.2
1.5
—
—
—
0
0
23
164
1.48
0.86
1.2
1.5
1.19
1.20
ratio
—
10
105
23
164
1.48
0.86
1.2
1.5
1.06
1.17
ratio
—
10
105
23
164
1.48
0.86
1.2
1.5
0.83
0.96
ratio
—
10
105
150
1472
+∞
0.77
29.6
17.8
134.19
134.89
g/l
0.33
150
1462
39
313
1.33
0.76
1.5
1.7
0.51
0.94
mg/l
1.07
30
227
5
24
2.12
0.75
1.0
1.3
—
—
—
0
0
7
40
1.79
0.72
3.3
2.0
—
—
—
0
0
7
40
1.79
0.72
1.0
1.6
—
—
—
0
0
11
164
0.64
0.66
1.6
2.9
190.97
367.53
ng/l
—
6
130
0
20
0.00
0.61
0.0
1.1
—
—
—
0
0
0
20
0.00
0.61
0.0
1.1
—
—
—
0
0
14
98
1.47
0.59
1.1
1.0
—
—
—
0
0
6
36
1.69
0.57
1.0
1.2
—
—
—
0
0
6
39
1.56
0.53
2.2
2.1
0.97
1.46
%
—
6
39
47
405
1.23
0.52
1.2
1.4
0.50
1.08
u/ml
—
7
118
6
40
1.52
0.52
3.5
2.0
—
—
—
0
0
13
176
0.71
0.49
1.7
2.8
0.85
0.83
mmol/l
0.64
13
168
43
370
1.23
0.48
2.0
2.8
2.32
2.34
mmol/l
0.47
37
345
116
1100
1.24
0.47
4.5
4.9
14.27
14.37
pmol/l
0.20
109
1049
16
205
0.75
0.44
1.3
1.8
3.48
3.36
mmol/l
—
9
138
25
301
0.80
0.43
1.6
2.0
—
—
—
0
0
115
1201
0.82
0.42
3.3
3.6
5.49
5.59
mmol/l
0.49
108
1138
0
15
0.00
0.41
0.0
2.7
—
2.67
—
0
9
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
0
18
0.00
0.40
0.0
2.6
—
20.16
—
0
9
0
19
0.00
0.39
0.0
1.5
—
—
—
0
0
8
111
0.71
0.39
1.8
1.6
—
—
—
0
0
9
70
1.30
0.37
1.1
1.3
2.99
2.77
ug/l
—
9
65
6
86
0.69
0.34
1.2
1.1
0.89
0.85
g/l
—
6
86
6
88
0.67
0.34
1.5
1.8
—
—
—
0
0
38
335
1.18
0.34
2.2
2.6
8.89
15.07
ng/l
1.82
18
145
51
461
1.16
0.33
2.1
2.3
—
—
—
0
0
25
292
0.83
0.33
1.2
1.3
11.50
8.28
u/ml
—
8
109
8
109
0.72
0.30
1.8
1.6
—
—
—
0
0
117
1128
1.17
0.29
3.3
4.7
35.05
36.88
mmol/mol
2.63
109
1091
21
246
0.83
0.28
1.5
1.9
—
—
—
0
0
6
85
0.69
0.24
1.2
1.1
1.60
1.58
g/l
—
6
85
5
39
1.29
0.23
1.0
1.9
4.16
3.63
g/l
—
5
39
33
297
1.14
0.23
3.1
3.2
1.02
1.02
kg/l
0.18
19
191
8
102
0.77
0.22
1.5
1.6
44.61
52.69
ug/l
—
8
102
8
103
0.76
0.22
2.3
2.4
—
—
—
0
0
23
202
1.16
0.21
1.5
1.6
—
—
—
0
0
28
312
0.87
0.21
1.3
1.4
22.20
19.03
iu/ml
—
5
84
5
42
1.20
0.21
1.6
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
217.03
—
0
11
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
194.24
—
0
10
0
10
0.00
0.21
0.0
2.8
—
52.40
—
0
10
0
10
0.00
0.21
0.0
1.2
—
76.10
—
0
10
0
12
0.00
0.21
0.0
2.8
—
0.79
—
0
6
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
6
49
1.23
0.20
1.7
1.9
210.25
165.92
%
—
6
49
19
217
0.86
0.20
1.9
1.8
1.34
1.35
%
0.04
19
196
33
301
1.12
0.19
1.4
1.6
900.55
941.63
mu/l
0.15
27
254
88
847
1.09
0.18
2.7
3.4
75.60
62.78
ug/l
0.81
83
816
121
1182
1.12
0.18
3.7
4.2
—
—
—
0
0
5
66
0.75
0.17
1.2
1.5
0.32
0.43
nmol/l
—
5
58
5
65
0.76
0.17
1.2
1.7
—
—
—
0
0
23
255
0.88
0.16
1.4
1.9
3.37
3.26
ratio
0.26
18
187
22
197
1.14
0.16
2.3
2.7
32.00
286.07
ng/l
1.05
11
86
10
84
1.20
0.14
1.2
1.3
—
—
—
0
0
16
180
0.88
0.14
1.1
1.3
184.00
138.31
u/ml
—
7
79
5
46
1.09
0.09
1.0
1.6
—
—
—
0
0
40
419
0.94
0.09
1.5
1.6
—
—
—
0
0
6
54
1.12
0.09
2.2
7.0
25.65
24.58
mmol/l
—
6
54
12
133
0.89
0.08
1.3
1.6
—
—
—
0
0
7
83
0.84
0.07
2.3
2.2
15.08
10.85
nmol/l
—
7
77
47
482
0.96
0.04
1.6
1.8
—
—
—
0
0
69
697
0.98
0.01
2.6
2.8
—
—
estimate
—
0
0
10
97
1.03
0.00
1.2
1.3
—
—
—
0
0
11
107
1.03
0.00
2.8
7.6
104.18
105.24
mmol/l
0.18
11
107
42
422
0.99
0.00
2.1
2.1
—
—
—
0
0
16
158
1.01
0.00
2.3
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.0
—
0.60
—
0
5
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
662.20
—
0
5
0
8
0.00
0.00
0.0
1.1
—
0.21
—
0
8
0
5
0.00
0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
32.40
—
0
5
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
5.2
—
18.22
—
0
9
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_PEGINTERFERONBETA1A – Use of peginterferon beta-1a
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).